U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06875297) titled 'A Single-center Prospective Interventional Study on FPG500 in Non-metastatic Prostate Cancer Patients' on March 04.
Brief Summary: The search for clinically actionable alterations within the non-metastatic prostate cancer setting has been an overlooked issue so far. Genomic alterations predicting tumor progression or representative of micrometastatic spread could be crucial to prompt the correct treatment strategy, sequencing and possible intensification in the high-risk and locally advanced settings. Similarly, the definition of the genomic landscape in low-risk patients progressing to more aggressive disease could be of importanc...